⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054943 | 0.87 | — | — | |
| Creatine SCHEMBL27865596 | 0.81 | NOS3 (0.43) | — | |
| Creatine SCHEMBL346039 | 0.81 | NOS3 (0.43) | — | |
| Creatine SCHEMBL8468423 | 0.81 | NOS3 (0.43) | — | |
| Creatine SCHEMBL4007614 | 0.80 | NOS3 (0.46) | — | |
| Creatine SCHEMBL27979093 | 0.80 | NOS3 (0.46) | — | |
| Creatine SCHEMBL30063981 | 0.80 | — | — | |
| Creatine SCHEMBL21567 | 0.80 | — | — | |
| SCHEMBL13862594 | 0.79 | — | — | |
| SCHEMBL18121933 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481383-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LTD (IN) | 2023-06-14 | — | — | EP | disclosed |
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| EP-3988108-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | Rhythm Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220048850-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | CELLIX BIO PRIVATE LTD (IN) | 2022-02-17 | — | — | US | disclosed |
| EP-3539551-B1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | RHYTHM PHARMACEUTICALS INC (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3539551-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | Rhythm Pharmaceuticals, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2797615-B1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | RHYTHM PHARMACEUTICALS INC (US) | 2019-04-03 | — | — | EP | disclosed |
| WO-2018115984-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | CELLIX BIO PRIVATE LIMITED (IN) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018087605-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | CELLIX BIO PRIVATE LIMITED (IN) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018029545-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2018-02-15 | — | — | WO | disclosed |
| US-7658936-B2 | Long term stability; low viscosity; minimal emulsifier content; oil in water soluton containing fatty alcohols, citric acid and partially neutralized monoglyceride and/or diglyceride fatty esters | GOLDSCHMIDT GMBH (DE) | 2010-02-09 | — | — | US | disclosed |
| US-7592019-B2 | Cosmetic or dermatological impregnated wipes | BEIERSDORF AG (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7511164-B2 | Enhanced bioavailability; reacting creatine, fatty acid and thionyl halide | MULTI FORMULATIONS LTD (CA) | 2009-03-31 | — | — | US | disclosed |
| US-20080206170-A1 | Creatine compositions for skin treatment | AVICENA GROUP, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080200723-A1 | CREATINE-FATTY ACIDS | MULTI FORMULATIONS LTD. (CA) | 2008-08-21 | — | — | US | disclosed |
| US-20080003208-A1 | Creatine-ligand compounds and methods of use thereof | AVICENA FROUP, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7314945-B1 | Creatine-fatty acids | MULTI FORMULATIONS LTD. (CA) | 2008-01-01 | — | — | US | disclosed |
| US-20070281996-A1 | Creatine prodrugs, compositions and uses thereof | XENOPORT, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070123453-A1 | Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion | ELI LILLY AND COMPANY | 2007-05-31 | — | — | US | disclosed |
| US-20070105759-A1 | Melanocortin receptor 4 (mc4) agonists and their uses | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |